(Q24245511)

PubMed

29 October 2023

2

Jan E Clarkson

J E

Clarkson

1 reference

PubMed

29 October 2023

Tim OB Eden

3

O B

Eden

1 reference

PubMed

17443513

Cochrane Database of Systematic Reviews

29 October 2023

language of work or name

1 reference

18 April 2007

0 references

published in

0 references

cites work

A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Routine versus selective antifungal administration for control of fungal infections in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Interventions for preventing oral mucositis for patients with cancer receiving treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Interventions for treating oral candidiasis for patients with cancer receiving treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

Interventions for treating oral mucositis for patients with cancer receiving treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Natamycin and nystatin for treatment of oral candidiasis during and after radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Ketoconazole and Candidiasis: A Controlled Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001972.PUB3

7 January 2021

10.1002/14651858.CD001972.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_6ulqi47jd5e4zk7vvw6c2aff5a

0 references